At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
HSC835drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Infusing HSC835 in Patients With Hematological Malignancies Undergoing UCB Transplantation Using a Non-myeloablative Conditioning Regimen
In Brief
A Phase 2 clinical trial evaluating HSC835 for Single Umbilical Cord Blood Transplantation and 6 related conditions. Completed, enrolled 9 participants across 1 site.
Detailed Summary
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB) transplantation (DUCBT) with non-myeloablative (NMA) conditioning.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSingle Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartOct 2014
Primary CompletionAug 2016
TodayJul 2026
First PostedAug 28, 2013
Enrollment StartOct 7, 2014
Primary CompletionAug 29, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.8 years ago
Interventions
HSC835drug
HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).